Atea Pharmaceuticals (AVIR) Operating Expenses (2019 - 2026)

Atea Pharmaceuticals' Operating Expenses history runs 8 years deep, the most recent figure standing at $48.0 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 22.97% year-over-year to $48.0 million; the TTM figure through Mar 2026 stood at $189.9 million (up 17.06% YoY), while the FY2025 annual figure was $180.9 million, down 6.25% from the prior year.
• Operating Expenses for Q1 2026 stood at $48.0 million, down from $54.9 million in the prior quarter.
• The five-year high for Operating Expenses was $69.8 million in Q1 2024, with the low at $16.3 million in Q3 2022.
• The 5-year median for Operating Expenses is $41.3 million (2025), against an average of $42.2 million.
• The sharpest annual moves came in 2022 and 2023: Operating Expenses sank 70.38% in 2022, then surged 150.51% in 2023.
• Atea Pharmaceuticals' Operating Expenses stood at $39.9 million in 2022, then increased by 16.73% to $46.6 million in 2023, then dropped by 16.2% to $39.0 million in 2024, then soared by 40.76% to $54.9 million in 2025, then fell by 12.61% to $48.0 million in 2026.
• Business Quant data shows AVIR's Operating Expenses at $48.0 million in Q1 2026, $54.9 million in Q4 2025, and $45.6 million in Q3 2025.